TABLE 1.
Baseline characteristics of the intervention group, patients switching to another anti‐CGRP‐mAb treatment, and controls receiving standard care.
| Switchers | Controls | p value | |
|---|---|---|---|
| Number of patients, n | 31 | 36 | |
| Age (years), mean ± SD | 41 (14) | 43 (12) | 0.503 |
| Sex (female), mean ± SD | 23 (74) | 32 (89) | 0.213 |
| BMI (kg/m2), mean ± SD | 24.9 (5.5) | 25.0 (4.8) | 0.933 |
| Migraine with aura, n (%) | 12 (39) | 21 (58) | 0.175 |
| Chronic migraine, n (%) | 15 (48) | 18 (50) | 1.000 |
| History of medication overuse headache, n (%) | 15 (48) | 21 (58) | 0.570 |
| Tension headache, n (%) | 13 (42) | 12 (33) | 0.637 |
| First CGRP medication a | |||
| Fremanezumab, n (%) | 14 (45) | 12 (33) | 0.460 |
| Erenumab, n (%) | 17 (55) | 24 (66) | |
| Days first CGRP were given, median ± IQR | 236 [168, 392] | 229 [152, 354] | 0.734 |
| Days between first and second CGRP‐mAbs, median ± IQR | 33 (29, 55) | – | – |
| Reasons treatment discontinuation | |||
| Poor treatment response, n (%) | 30 (97) | 28 (78) | 0.050 |
| Adverse events, n (%) | 1 (3.2) | 6 (16.7) | |
| Desire for pregnancy, n (%) | 0 (0.0) | 2 (5.6) | |
| MMD baseline, mean ± SD | 13.3 (6.8) | 13.6 (7.0) | 0.848 |
| MHD baseline, mean ± SD | 17.6 (7.7) | 17.4 (7.9) | 0.920 |
| Acute medication days baseline, mean ± SD | 5.7 (3.4) | 4.8 (2.9) | 0.298 |
| Completed diaries at baseline, median ± IQR | 28 (27–28) | 28 (27–28) | 0.698 |
| MMD baseline (imputed) b | 13.7 (6.8) | 14.2 (7.30) | 0.802 |
| MHD baseline(imputed) b | 18.2 (7.8) | 18.1 (8.1) | 0.957 |
Note: Comparisons between intervention and control group at baseline were performed using an unpaired t test for continuous variables, a chi‐squared test for categorical data and a Mann–Whitney U test for non‐normally distributed data.
Abbreviations: BMI, body mass index; CGRP, anti‐calcitonin gene‐related peptide; CGRP‐mAb, anti‐calcitonin gene‐related peptide monoclonal antibody; IQR, interquartile range; MHD, monthly headache day; MMD, monthly migraine day.
In this sample patients started with either fremanezumab or erenumab.
A ratio imputation was performed for patients missing ≤10 days at baseline (in total 3.6%).